Popular Trials
Janus Kinase (JAK) Inhibitor
Ritlecitinib for Cutaneous T-Cell Lymphoma
Recruiting1 awardPhase 2
New York, New York
This trial is testing a new drug to treat Cutaneous T-Cell Lymphoma, a type of blood cancer that can cause skin rashes/tumors. Tests incl. physical/visual exams, lab tests, skin biopsies, and more. Results will be monitored over 48 weeks.
Popular Filters
Trials for MF Patients
Checkpoint Inhibitor
Cemiplimab for Cutaneous T-Cell Lymphoma
Recruiting1 awardPhase 1 & 2
Edmonton, Alberta
This trial is testing whether the immunotherapy drug cemiplimab can help to treat patients with mycosis fungoides who have failed first line therapy. The primary objective is to see what the response rate is for these patients.
Monoclonal Antibodies
Total-Skin Electron Beam Therapy + Brentuximab for Skin Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing a combination of low-dose skin radiation and a targeted cancer drug. It focuses on patients with a specific type of skin lymphoma that is hard to treat. The treatment works by using radiation to reduce cancer cells on the skin and a drug to kill them directly.
Monoclonal Antibodies
Pembrolizumab + Gemcitabine for Cutaneous T-Cell Lymphoma
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a combination of two drugs, pembrolizumab and gemcitabine, to treat patients with mycosis fungoides and Sézary syndrome. Pembrolizumab helps the immune system attack cancer, while gemcitabine kills cancer cells directly. The goal is to see if this combination is more effective than current treatments. IPH4102 is a new antibody specifically developed for treating cutaneous T-cell lymphoma.
Radiation
Mogamulizumab + LD TSEBT for Cutaneous Lymphoma
Recruiting1 awardPhase 2
Stanford, California
This trial is testing a combination of two drugs to see if it is effective in treating patients with mycosis fungoides or Sézary syndrome. It will also look at the safety and side effects of the combination.
Trials for Cutaneous T-Cell Lymphoma Patients
Monoclonal Antibodies
Pembrolizumab + Gemcitabine for Cutaneous T-Cell Lymphoma
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a combination of two drugs, pembrolizumab and gemcitabine, to treat patients with mycosis fungoides and Sézary syndrome. Pembrolizumab helps the immune system attack cancer, while gemcitabine kills cancer cells directly. The goal is to see if this combination is more effective than current treatments. IPH4102 is a new antibody specifically developed for treating cutaneous T-cell lymphoma.
CAR T-cell Therapy
CAR-T Cell Therapy for Lymphoma
Recruiting1 awardPhase 1
Chapel Hill, North Carolina
This trial tests a new treatment using lab-modified immune cells to target and kill cancer cells in patients with certain types of lymphoma that haven't responded to other treatments. The modified cells are designed to better locate and destroy cancer cells. This new approach extends the capacity of the patient's own immune cells to detect and eliminate cancer cells.
Trials With No Placebo
Checkpoint Inhibitor
Cemiplimab for Cutaneous T-Cell Lymphoma
Recruiting1 awardPhase 1 & 2
Edmonton, Alberta
This trial is testing whether the immunotherapy drug cemiplimab can help to treat patients with mycosis fungoides who have failed first line therapy. The primary objective is to see what the response rate is for these patients.
Monoclonal Antibodies
Total-Skin Electron Beam Therapy + Brentuximab for Skin Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing a combination of low-dose skin radiation and a targeted cancer drug. It focuses on patients with a specific type of skin lymphoma that is hard to treat. The treatment works by using radiation to reduce cancer cells on the skin and a drug to kill them directly.
Monoclonal Antibodies
Pembrolizumab + Gemcitabine for Cutaneous T-Cell Lymphoma
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a combination of two drugs, pembrolizumab and gemcitabine, to treat patients with mycosis fungoides and Sézary syndrome. Pembrolizumab helps the immune system attack cancer, while gemcitabine kills cancer cells directly. The goal is to see if this combination is more effective than current treatments. IPH4102 is a new antibody specifically developed for treating cutaneous T-cell lymphoma.
Radiation
Mogamulizumab + LD TSEBT for Cutaneous Lymphoma
Recruiting1 awardPhase 2
Stanford, California
This trial is testing a combination of two drugs to see if it is effective in treating patients with mycosis fungoides or Sézary syndrome. It will also look at the safety and side effects of the combination.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.